Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745743 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of BAY1251152 for Advanced Blood Cancers
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02745743 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 21 participants.
The verdict
NCT02745743, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of the study drug. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.
Interventions
- DRUG BAY1251152
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-06-17 |
| Est. Completion | 2018-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02745743
The ClinicalTrials.gov registry entry for NCT02745743 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY1251152 is the first listed.
NCT02745743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02745743 about?
NCT02745743 is a clinical study titled "Phase I Trial of BAY1251152 for Advanced Blood Cancers". The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of the study d...
What is the current status of trial NCT02745743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-06-17. Estimated completion is 2018-08-03.
What interventions are being tested in trial NCT02745743?
The interventions under investigation include: BAY1251152 (DRUG).
Who is sponsoring clinical trial NCT02745743?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.